Edap Tms S.A. (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Wednesday. <\/p>\n
According to Zacks, EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. <\/p>\n
Separately, TheStreet raised Edap Tms from a sell rating to a hold rating in a research note on Tuesday, September 27th. <\/p>\n
Edap Tms (NASDAQ:EDAP) traded up 0.29% during midday trading on Wednesday, reaching $3.42. The companys stock had a trading volume of 54,479 shares. Edap Tms has a 1-year low of $2.43 and a 1-year high of $4.80. The company has a 50 day moving average price of $3.23 and a 200 day moving average price of $3.04. The firm has a market cap of $98.25 million, a price-to-earnings ratio of 8.61 and a beta of 1.29. <\/p>\n
An institutional investor recently raised its position in Edap Tms stock. Wells Fargo & Company MN boosted its stake in shares of Edap Tms S.A. (NASDAQ:EDAP) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 193,655 shares of the companys stock after buying an additional 2,000 shares during the period. Wells Fargo & Company MN owned 0.67% of Edap Tms worth $562,000 at the end of the most recent quarter. 9.56% of the stock is owned by institutional investors and hedge funds. <\/p>\n
Edap Tms Company Profile <\/p>\n
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. <\/p>\n
Get a free copy of the Zacks research report on Edap Tms (EDAP) <\/p>\n
For more information about research offerings from Zacks Investment Research, visit Zacks.com <\/p>\n
<\/p>\n
Go here to see the original:<\/p>\n
The Zacks Investment Research Upgrades Edap Tms SA (EDAP) to Hold - DailyQuint<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Edap Tms S.A. Continue reading